Followers | 9840 |
Posts | 260002 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Wednesday, November 06, 2019 5:35:02 PM
Link to Video - click here to watch the technical chart video
Recent AMRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/03/2024 10:14:36 AM
- Amneal Reports First Quarter 2024 Financial Results • Business Wire • 05/03/2024 10:00:00 AM
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose • Business Wire • 04/24/2024 12:00:00 PM
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine • Business Wire • 04/16/2024 12:00:00 PM
- Amneal to Report First Quarter 2024 Results on May 3, 2024 • Business Wire • 04/10/2024 12:00:00 PM
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 • Business Wire • 03/28/2024 08:05:00 PM
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension • Business Wire • 03/25/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/22/2024 12:01:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/22/2024 12:01:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:40:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:39:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:54:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 11:13:05 AM
- Amneal Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/01/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:25:51 PM
- Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 • Business Wire • 02/27/2024 01:00:00 PM
- Amneal to Participate at Upcoming Investor Conference • Business Wire • 02/13/2024 01:00:00 PM
- Amneal Announces Complete Response Resubmission for IPX203 New Drug Application • GlobeNewswire Inc. • 02/08/2024 09:05:00 PM
- Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 • Business Wire • 01/31/2024 09:05:00 PM
- Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension • Business Wire • 01/10/2024 01:00:00 PM
- Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023 • Business Wire • 01/04/2024 09:05:00 PM
- Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 12/26/2023 09:10:26 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 12/26/2023 09:05:25 PM
- Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/21/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM